世界*实验材料供应商 BioCheck上海金畔生物为其中国代理， BioCheck在一直是行业的*,一直为广大科研客户提供zui为的产品和服务,上海金畔生物一直秉承为中国科研客户带来的产品，的服务， BioCheck就是为了给广大科研客户带来更加完善的产品和服务,您的满意将是我们zui大的收获
BioCheck中国代理, BioCheck上海代理， BioCheck北京代理，BioCheck广东代理， BioCheck江苏代理BioCheck湖北代理,BioCheck天津,BioCheck黑龙江代理,BioCheck内蒙古代理,BioCheck吉林代理,BioCheck福建代理, BioCheck江苏代理, BioCheck浙江代理, BioCheck四川代理
BIOCHECK公司由创始人 Dr. John Chen, Medix创立, 是一家抓也提供肿瘤标志物，心肌标志物，激素类zui高性价比的抗体的公司。
简要原理
利用竞争酶联免疫方法，预先在微孔中包被羊抗兔抗体，实验时先后加入氯霉素标准品或待测样本，氯霉素酶标抗原和兔抗氯霉素抗体。经过室温温育，反应液中的兔抗氯霉素抗体与微孔板上的羊抗兔抗体结合，待测样品中的抗原与氯霉素酶标抗原竞争微孔板上的兔抗氯霉素抗体。洗涤后，没有与抗
体结合的待测样品中的抗原或酶标抗原被洗去，再加入反应底物，结合的酶标抗原的酶将底物转化为蓝色产物，加入终止液后颜色由蓝色变为黄色。反应完成后，样品中氯霉素含量越多，反应呈色就越浅；反之，样品中氯霉素含量越少，则呈色越深。利用标准曲线可计算出样品中氯霉素含量。
技术参数
检测蜂蜜、蛋类、牛奶、奶粉、水产品、动物组织(肌肉、肝脏等)、饲料、血清、血浆及尿液样本中存在的氯霉素，定量限可达0.025 ppb。
|
No. |
样品 |
检测下限 |
|
1 |
蜂蜜 |
0.02 ppb (0.02 ng/g) |
|
2 |
蛋类 |
0.02 ppb (0.02 ng/g) |
|
3 |
牛奶 |
0.002 ppb (0.002 ng/ml) |
|
4 |
奶粉 |
0.012 ppb (0.012 ng/g) |
|
5 |
虾，鱼及肉类 |
0.08 ppb (0.08 ng/g) |
|
6 |
饲料 |
0.08 ppb (0.08 ng/g) |
|
7 |
血清/血浆 |
0.02 ppb (0.02 ng/ml) |
|
8 |
尿液 |
0.04 ppb (0.04 ng/ml) |
交叉反应
|
名称 |
百分比 |
|
氯霉素碱 |
0.4% |
|
甲基氯霉素 |
<0.04% |
回收率
|
No. |
样品 |
回收率 |
|
1 |
蜂蜜 |
70% ~ 110% |
|
2 |
牛奶 |
90% ~ 130% |
|
3 |
蛋，虾，鱼及肉类 |
95% ~ 120% |
|
4 |
饲料 |
95% ~ 120% |
|
5 |
血清 / 血浆 |
90% ~ 120% |
|
6 |
尿液 |
100% ~ 130% |
PD-L1 ENZYME IMMUNOASSAY TEST KIT
Catalog Number: BC-1303
Enzyme Immunoassay for the Quantitative Determination of PD-L1 Concentration in Human Serum and Plasma
FOR RESEARCH USE ONLY
Not for use in diagnostic procedures
INTRODUCTION
Programmed death receptor-ligand 1 (PD-L1, B7- H1, CD274) is a biomarker from the B7 family that is expressed on a variety of cells and upregulated in response to pro-inflammatory cytokines such as interferon gamma1,2,3. PD-L1 interacts with PD-1, a co-receptor expressed by exhausted T cells, to encourage an immunosuppressive tumor microenvironment by decreasing T cell receptor mediated proliferation and cytokine production4, 5. The PD-1/PD-L1 interaction functions as an immune checkpoint in a process known as immunoediting where the host immune system eliminates highly immunogenic tumors while allowing less immunogenic tumor to evade it2, 6. Multiple solid tumor types including melanoma, renal cell carcinoma, non-small cell lung cancer, ovarian, and colorectal cancer utilize this PD-1/PD -L1 immunoediting mechanism2. Current treatment has focused on blocking the PD-1/PD-L1 interaction to reduce tumor evasion by inhibiting PD-1, with new focus on PD-L1 as well1, 2.
PRINCIPLE OF THE ASSAY
The PD-L1 ELISA is based on the principle of a solid phase enzyme-linked immunosorbent assay. The assay system utilizes a unique monoclonal antibody pair directed against a distinct antigenic determinant on the PD-L1 molecule. One mouse monoclonal anti- PD- L1 antibody is used for solid phase immobilization (on the microtiter wells). Another mouse monoclonal anti-PD-L1 antibody conjugated to horseradish peroxidase (HRP) is in the enzyme conjugate solution. The test samples are allowed to react sequentially with the two antibodies, resulting in the PD-L1 molecules to be sandwiched between the solid phase and enzyme-linked antibodies. After two separate 60- minute incubation steps at room temperature, the wells are rinsed with Wash Buffer to remove unbound labeled antibodies. TMB Reagent is added and incubated for 30 minutes under dark conditions, resulting in the development of a blue color. The color development is stopped with the addition of Stop Solution, changing the color to yellow. The concentration of
PD-L1 is directly proportional to the color intensity of the test samples. Absorbance is measured spectrophotometrically at 450 nm.
REAGENTS AND MATERIALS PROVIDED
- Antibody-Coated Wells (1 plate, 96 wells)
Microtiter wells coated with mouse monoclonal anti-PD-L1
- 20 ng/ml PD-L1 Standard (0.5 mL /vial)
20 ng/mL PD-L1 in phosphate buffer-BSA solution with preservatives
3. Standard and Sample Diluent (30 mL/bottle, 1 bottle)
Contains phosphate buffer-BSA solution with preservatives
- Enzyme Conjugate Reagent (12 mL/vial, 1 vial)
Contains mouse monoclonal anti-PD-L1 conjugated to horseradish peroxidase
- 20X Wash Buffer (50 mL/bottle, 1 bottle) Phosphate buffer with detergents
- TMB Reagent (11 mL/bottle, 1 bottle)
Contains one-step TMB solution
- Stop Solution (11 mL/bottle, 1 bottle)
Contains diluted hydrochloric acid (1N HCl)
STORAGE CONDITIONS
- Store the unopened kit at 2-8°C upon receipt and when it is not in use, until the expiration shown on the kit label. Refer to the package label for the expiration date.
- Keep microtiter plate in a sealed bag with desiccant to minimize exposure to damp air.
REAGENT PREPARATION
- All reagents should be allowed to reach room temperature (18-25°C) before use.
- For each test run, prepare a fresh standard set.
- Dilute 20 ng/mL standard to 5 ng/mL. Prepare two-fold serial dilutions of the 5 ng/mL Standard with Standard/Sample Diluent:
- 5 ng/mL: 0.15 mL of 20 ng/mL+ 0.45 mL of Standard/Sample Diluent
- 2.5 ng/mL: 0.25 mL of 5 ng/mL+ 0.25 mL of Standard /Sample Diluent
- 1.25 ng/mL: 0.25 mL of 2.5 ng/ml + 0.25 mL of Standard/Sample Diluent
- 0.625 ng/mL: 0.25 mL of 1.25 ng/mL + 0.25 mL of Standard/Sample Diluent
- 0.313 ng/mL: 0.25 mL of 0.625 ng/mL + 0.25 mL of Standard/Sample Diluent
- 0.156 ng/mL: 0.25 mL of 0.313 ng/mL + 0.25 mL of Standard Diluent
- 0.078 ng/mL: 0.25 mL of 0.156 ng/mL + 0.25 mL of Standard Diluent
- 0 ng/mL: 0.25 mL of Standard Diluent
- Patient samples need to be diluted 4-fold prior to use. Prepare a series of small tubes (i.e., 1.5 mL microcentrifuge tubes) and mix 60 µL of serum with 180 µLStandard/Sample Diluent.
- Working Wash Buffer: Preparation of 1X Wash Buffer from 20X Stock. Add 50 mL of 20X Wash Buffer Stock to 950 mL of DI H2O. The Working Wash Buffer is stable at 2-8°C for 30 days. NOTE: Any crystals that may be present due to high salt concentration must be redissolved at room temperature before making the dilution.
ASSAY PROCEDURE
- Prepare Standards. See Reagent Preparation.
- Dilute samples 1:4 dilution. See Reagent Preparation.
- Secure the desired number of coated wells in the holder.
- Dispense 100 m L of PD-L1 standards, and DILUTED specimens into the appropriate wells.
- Incubate for 60 minutes at room temperature (18-25 °C).
- Remove incubation mixture by flicking plate contents into a waste container. Rinse and flick the microtiter wells 5 times with 300 m L Working Wash Buffer. Strike the wells onto absorbent paper or paper towels to remove all residual water droplets.
- Dispense 100 m L of PD-L1 Working Enzyme Conjugate Reagent into each well.
- Incubate for 60 minutes at room temperature (18-25 °C).
- Remove incubation mixture by flicking plate contents into a waste container. Rinse and flick the microtiter wells 5 times with 300 uL Working Wash Buffer. Strike the wells onto absorbent paper or paper towels to remove all residual water droplets.
- Dispense 100 mL TMB solution into each well.
- Incubate for 30 minutes at room temperature (18-25 °C).
- Stop the reaction by adding 100 mL of Stop Solution into each well.
- Gently mix for 30 seconds. It is important to make sure that all the blue color changes to yellow color compley.
- Read absorbance at 450 nm with a microtiter well reader within 15 minutes.
CALCULATION OF RESULTS
- Calculate the mean absorbance value (OD450) for each set of reference standards, controls and samples.
- Construct a standard curve by plotting the mean absorbance obtained for each reference standard against its concentration in ng/ml on graph paper, with absorbance on the vertical (y) axis and concentration on the horizontal (x) axis.
- The corresponding concentration of PD-L1 (ng/mL) can be determined from the standard curve using the mean absorbance value for each sample. Depending on experience and/or the availability of computer capability, other methods of data reduction may be employed.
- The obtained values of the samples should be multiplied by the dilution factor of 4 to obtain PD-L1 results in ng/ml.
EXAMPLE OF STANDARD CURVE
Results of a typical standard run with absorbency readings at 450 nm shown on the Y axis against PD-L1 concentrations shown on the X axis. NOTE: This standard curve is for the purpose of illustration only, and should not be used to calculate unknowns. Each laboratory must generate its own data and standard curve in each experiment.
|
PD-L1 |
Absorbance |
|
(ng/ml) |
(450 nm) |
|
0 |
0.042 |
|
0.078 |
0.141 |
|
0.156 |
0.236 |
|
0.313 |
0.415 |
|
0.625 |
0.726 |
|
1.25 |
1.283 |
|
2.5 |
2.100 |
|
5 |
3.053 |
|
nm |
3.5 |
|
|
|
|
|
|
3 |
|
|
|
|
|
|
|
(450 |
|
|
|
|
|
|
|
2.5 |
|
|
|
|
|
|
|
2 |
|
|
|
|
|
|
|
Absorbance |
|
|
|
|
|
|
|
1.5 |
|
|
|
|
|
|
|
1 |
|
|
|
|
|
|
|
0.5 |
|
|
|
|
|
|
|
0 |
|
|
|
|
|
|
|
|
0 |
1 |
2 |
3 |
4 |
5 |
|
|
|
|
PD-L1 Conc. (ng/ml) |
|
||
PERFORMANCE CHARACTERISTICS
- Sensitivity
The minimum detectable concentration of the PD-L1 ELISA assay as measured by 2SD from the mean of a zero standard is estimated to be 0.02 ng/ml.
- Precision
- Intra-Assay Precision
Within-run precision was determined by replicate determinations of three different samples in one assay. Within-assay variability is shown below:
|
Sample |
1 |
2 |
3 |
|
# Replicates |
24 |
24 |
24 |
|
Mean PD-L1 (ng/mL) |
1.5 |
3.0 |
7.4 |
|
S.D. |
0.04 |
0.05 |
0.18 |
|
C.V. (%) |
2.4% |
1.6% |
2.4% |
2
- Inter-Assay Precision
Between-run precision was determined by replicate measurements of three different samples over a series of individually calibrated assays. Between-assay variability is shown below:
|
Sample |
1 |
2 |
3 |
|
# Replicates |
20 |
20 |
20 |
|
Mean PD-L1 (ng/mL) |
1.6 |
3.0 |
7.4 |
|
S.D. |
0.04 |
0.12 |
0.26 |
|
C.V. (%) |
2.5% |
4.1% |
3.5% |
- Recovery and Linearity Studies
- Recovery
Samples were spiked with known PD-L1 levels and assayed in duplicate. The mean recovery was 90%.
|
Sample |
EXPECTED |
OBSERVED |
% RECOVERY |
|
|
[PD-L1] |
[PD-L1] |
|
|
|
(ng/mL) |
(ng/mL) |
|
|
1 |
2 |
1.8 |
90% |
|
2 |
5 |
4.6 |
92% |
|
3 |
10 |
8.9 |
89% |
- Linearity
Three samples were serially diluted to determine linearity. The mean recovery was 110.3%.
|
# |
Dilution |
Expected |
Observed |
|
|
|
|
Conc. (ng/ml) |
Conc. (ng/ml) |
% Expected |
|
1. |
1:4 |
1.6 |
1.6 |
N/A |
|
|
1:8 |
|
1.7 |
106.3% |
|
|
1:16 |
|
1.7 |
106.3% |
|
|
1:32 |
|
1.8 |
112.5% |
|
|
|
|
|
Mean = 108.4% |
|
2. |
1:4 |
3.7 |
3.7 |
N/A |
|
|
1:8 |
|
4.0 |
108.1% |
|
|
1:16 |
|
4.0 |
108.1% |
|
|
1:32 |
|
4.1 |
110.8% |
|
|
|
|
|
Mean = 109.0% |
|
|
|
|
|
|
|
3. |
1:4 |
7.4 |
7.4 |
N/A |
|
|
1:8 |
|
8.3 |
112.2% |
|
|
1:16 |
|
8.6 |
116.2% |
|
|
1:32 |
|
8.3 |
112.2% |
Mean = 113.5%
REFERENCES
- Herbst, Roy S., et al. “Predictive correlates of response to the
anti-PD-L1 antibody MPDL3280A in cancer
patients.” Nature 515.7528 (2014): 563.
- Pa, Sandip Pravin, and Razelle Kurzrock. “PD-L1 expression as a predictive biomarker in cancer immunotherapy.” Molecular cancer therapeutics 14.4 (2015): 847-856.
- Topalian, Suzanne L., Charles G. Drake, and Drew M. Pardoll. “Targeting the PD-1/B7-H1 (PD-L1) pathway to activate anti-tumor immunity.” Current opinion in immunology 24.2 (2012): 207-212.
- Blank, Christian, and Andreas Mackensen. “Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion.” Cancer immunology, immunotherapy 56.5 (2007): 739-745.
- Barber, Daniel L., et al. “Restoring function in exhausted CD8 T cells during chronic viral infection.” Nature 439.7077 (2006): 682.
- Teng, Michele WL, et al. “Classifying cancers based on T-cell infiltration and PD-L1.” Cancer research 75.11 (2015): 2139-2145.
部分产品如下：
| 货号 | 品名 | Tests/Kit | 规格 | 品牌 |
| 70748 | Mouse Monoclonal anti-human PD-1 (Capture) | Purified | 0.1/0.5/1 mg | BioCheck |
| 70749 | Mouse Monoclonal anti-human PD-1 (Capture) | Purified | 0.1/0.5/1 mg | BioCheck |
| 70750 | Mouse Monoclonal anti-human PD-1 (Detection) | Purified | 0.1/0.5/1 mg | BioCheck |
| 70751 | Mouse Monoclonal anti-human PD-L1 (Capture) | Purified | 0.1/0.5/1 mg | BioCheck |
| 70752 | Mouse Monoclonal anti-human PD-L1 (Capture) | Purified | 0.1/0.5/1 mg | BioCheck |
| 70753 | Mouse Monoclonal anti-human PD-L1 (Detection) | Purified | 0.1/0.5/1 mg | BioCheck |
| 70745 | Mouse monoclonal anti-human Lp-PLA2 (Capture) | Purified | 0.5 mg | BioCheck |
| 70746 | Mouse monoclonal anti-human Lp-PLA2 (Detection) | Purified | 0.5 mg | BioCheck |
| 70747 | Mouse monoclonal anti-human Lp-PLA2 (Detection) | Purified | 0.5 mg | BioCheck |